MedGenome, a prominent global precision medicine company specializing in omics solutions, has recently appointed Martin Dewhurst as the Chairman of its Advisory Board. With over 30 years of experience at McKinsey, where he led the global life sciences practice for seven years, Martin brings a wealth of expertise to guide and advance MedGenome’s mission in leveraging omics to address global healthcare needs.
In his role as Chairman of the Advisory Board, Martin will collaborate closely with MedGenome’s Research services team in the US, aiming to build strong connections within the global life science community. His strategic vision and extensive experience in both technology and life sciences will play a critical role in fostering collaborations with scientific leaders and guiding the company’s omics research initiatives.
Over the past decade, MedGenome has evolved into a digital-first company, focusing on improving healthcare access for emerging consumers and providing cutting-edge research and insights globally. Martin’s appointment aligns with MedGenome’s commitment to developing an ecosystem reflective of the diverse consumers in global healthcare.
Dr. Felix Olale, Chairman of MedGenome’s Board of Directors, expressed excitement about Martin’s appointment, stating that his strategic vision and experience will strengthen MedGenome’s position as a leader in the global omics space.
Mahesh Pratapneni, Group CEO & Co-founder of MedGenome, emphasized Martin’s impressive track record and deep understanding of the global healthcare landscape, anticipating his valuable contributions in building long-term relationships with the scientific community.
Martin Dewhurst, in his statement, expressed confidence in MedGenome’s role in anchoring the future of the life sciences sector. He praised MedGenome’s technology platform and research solutions, positioning the company as a key player and leader in advancing omics research for progress in the field.
Martin, known for his roles in growth VC investing, M&A advisory, and board positions, has been a vital
contributor to growth and innovation in various dynamic companies, including Distalmotion and now MedGenome.
MedGenome, a genomics-driven research and diagnostics company, focuses on improving global health by decoding genetic information. With access to a diverse genomic database and strong scientific expertise, MedGenome accelerates research, enhances cost efficiencies, and facilitates faster drug development. Backed by a global investor base, including support from Novo Holdings, MedGenome operates a high-throughput next-generation sequencing lab in Foster City, California. Martin Dewhurst’s appointment signifies a significant step in advancing MedGenome’s presence in the global omics market.
